ABK

ABK Beer extend partnership with Laser Tools Racing with MB Motorsport ahead of 2024 BTCC title charge

Retrieved on: 
Tuesday, March 26, 2024
Retail, Automotive, Sports, Other Automotive, Wine & Spirits, Motor Sports, Licensing (Sports), ABK, Partnership, BTCC, Beer, News

Laser Tools Racing with MB Motorsport are delighted to have strengthened its partnership with ABK Beer, the award-winning, handcrafted beer brewed in Bavaria, for the duration of the 2024 Kwik Fit British Touring Car Championship.

Key Points: 
  • Laser Tools Racing with MB Motorsport are delighted to have strengthened its partnership with ABK Beer, the award-winning, handcrafted beer brewed in Bavaria, for the duration of the 2024 Kwik Fit British Touring Car Championship.
  • Having enjoyed plenty of success together since 2022, the news continues the strong working relationship held between ABK Beer, the ROKiT Group and MB Motorsport into another racing season.
  • With fan favourite Jake Hill behind the wheel of the MB Motorsport BMW 330e M Sport, ABK Beer will be proudly displayed as the team looks to take their recent success to new heights in 2024.
  • Mark Blundell Sporting Director of Laser Tools Racing with MB Motorsport concluded: “It is fantastic to see ABK Beer involved again in 2024.

ABK Beer becomes Official Beer of Rugby League

Retrieved on: 
Monday, February 5, 2024
Retail, Sports, Other Sports, Wine & Spirits, Licensing (Sports), Food, Beverage, Collegiate summer baseball, Partnership, Super League, Rugby league in England, Magic Weekend, History, Magic, Superbike World Championship, Beer, FIA, Challenge Cup, ABK, Foot, BMW, Rugby league

RL Commercial have today announced a major new partnership for the sport with ABK Beer, one of the oldest and most popular breweries in Germany, becoming the Official Beer of Rugby League.

Key Points: 
  • RL Commercial have today announced a major new partnership for the sport with ABK Beer, one of the oldest and most popular breweries in Germany, becoming the Official Beer of Rugby League.
  • ABK Beer will have rights across the Betfred Super League, Betfred Challenge Cup and England Rugby League.
  • The staff at ROKiT Drinks have been great to work with and have fully bought into Rugby League and our ethos.
  • Jonathan Kendrick, Chairman and co-Founder of ROKiT, added, "We're very excited that ABK Beer has become the official beer of Rugby League, not just because we know rugby fans appreciate excellent beer, but also the history and ethos of Rugby League sit very well with the traditions and values of our 700 year old brewery."

ABK's Edel Beer Wins Gold Medal at the European Beer Star Awards – Again!

Retrieved on: 
Wednesday, November 29, 2023
Retail, Consumer, Restaurant, Bar, Wine & Spirits, Women, Specialty, Men, Gold, Beer, Silver, ABK

Long-recognised as one of the world’s most prestigious competitions in the brewing industry, the European Beer Star Awards 2023 involved a 150-strong international jury of beer experts, including master brewers, trade journalists and beer sommeliers, blind-tasting 2,356 beers from around the world across 74 different beer styles with gold, silver and bronze awarded in each category.

Key Points: 
  • Long-recognised as one of the world’s most prestigious competitions in the brewing industry, the European Beer Star Awards 2023 involved a 150-strong international jury of beer experts, including master brewers, trade journalists and beer sommeliers, blind-tasting 2,356 beers from around the world across 74 different beer styles with gold, silver and bronze awarded in each category.
  • ABK’s Edel beer emerged victorious once again.
  • “It’s an astonishing achievement for our brewery to, yet again, win Gold at the Beer Star Awards,” said Jonathan Kendrick, Chairman and co-Founder of ROKiT Drinks, part of the ROKiT Group of Companies.
  • ABK Beer is part of ROKiT Drinks which is part of the ROKiT group of Companies co-founded by Jonathan Kendrick and John Paul DeJoria.

ABK Biomedical announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

Retrieved on: 
Tuesday, December 5, 2023
Microparticle, HCC, Research, Safety, Patient, Hepatocellular carcinoma, Food, IDE, ABK, Diagnosis, FDA, Pharmaceutical industry, NS

HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc. , an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc. , an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
  • This designation is for the proposed Eye90 microspheres indication for the treatment of patients living with unresectable Hepatocellular Carcinoma (HCC).
  • "We are pleased with the FDA's decision to grant Breakthrough Device Designation for Eye90 microspheres Y90 radioembolization device.
  • Dr. Aravind Arepally, Chief Medical Officer of ABK Biomedical, stated, "Eye90 microspheres radioembolization marks a significant breakthrough in the treatment of HCC.

ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

Retrieved on: 
Tuesday, October 24, 2023
Radiation therapy, FDA, HCC, Trial of the century, Incidence, Microparticle, NS, Research, Liver cancer, Cancer, Safety, Patient, ABK, Medical imaging, MD

The Eye90 microspheres radioembolization procedure was performed by Eric A. Wang, MD, FSIR, with Charlotte Radiology in Charlotte NC.

Key Points: 
  • The Eye90 microspheres radioembolization procedure was performed by Eric A. Wang, MD, FSIR, with Charlotte Radiology in Charlotte NC.
  • The Route90 pivotal clinical study is designed to evaluate the safety and efficacy of Eye90 microspheres in patients living with unresectable HCC.
  • The study will evaluate HCC tumors' response rates and duration of response from Eye90 microspheres treatment as co-primary endpoints.
  • "The Route90 pivotal study will not only confirm the effectiveness of Eye90 treatment but will also establish the importance of 3D radiation dosimetry in advancing therapy and patient outcomes.

ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma

Retrieved on: 
Tuesday, May 30, 2023
Investigational device exemption, Hepatocellular carcinoma, ABK, Research, Radiation therapy, MD, Patient, NS, Principal, IDE, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Microparticle, HCC, Food, Safety, Medical device, Medical imaging

The pivotal clinical study, Route90, is designed to evaluate the safety and efficacy of Eye90 microspheres in patients living with unresectable Hepatocellular Carcinoma (HCC).

Key Points: 
  • The pivotal clinical study, Route90, is designed to evaluate the safety and efficacy of Eye90 microspheres in patients living with unresectable Hepatocellular Carcinoma (HCC).
  • The Route90 study will evaluate HCC tumors' response rates and duration of response from Eye90 microspheres treatment as co-primary endpoints.
  • "We're motivated to begin this pivotal study and assess the Eye90 microspheres technology in a large well-controlled, well-designed study.
  • Mike Mangano, President, and CEO, ABK Biomedical , said: "FDA approval of this pivotal study is a significant milestone for ABK.

Ultimate Medical Academy Highlights 118 Students Becoming ABK Honor Society Members

Retrieved on: 
Wednesday, February 1, 2023
Online, Destiny, UMA, Medical billing, University, CGPA, Character, Student, ABK, Health, Diploma, National Honor Society, Alpha Beta Kappa, Ultimate Medical Academy, United States Department of Health and Human Services, Associate, Amber, Bureau of Labor Statistics, Medicine, Interior design, Science, Coding

Tampa, Florida, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The Online Campus of Ultimate Medical Academy, a non-profit healthcare educational institution committed to equipping and empowering students to succeed, is celebrating 118 students being inducted into the Alpha Beta Kappa (ABK) National Honor Society.

Key Points: 
  • Tampa, Florida, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The Online Campus of Ultimate Medical Academy, a non-profit healthcare educational institution committed to equipping and empowering students to succeed, is celebrating 118 students being inducted into the Alpha Beta Kappa (ABK) National Honor Society.
  • These dedicated students are prepared to help fill critical needs in the healthcare industry.
  • The U.S. Bureau of Labor Statistics projects that 16.97 million workers are needed to fill open healthcare positions from 2021 to 2031.
  • “UMA is proud to recognize these exemplary students who are dedicating their lives to helping others,” said Lisa McClure, Vice President of Programs and Academic Affairs.

ABK Biomedical Raises USD 30M in Series C Financing

Retrieved on: 
Tuesday, December 6, 2022
Ketan, Capital, Biomedicine, Physician, NS, R, Medtech, Partnership, Patient, Eight Roads Ventures, Research, GMP, Microparticle, FDA, Trial of the century, Multimedia, Liver cancer, ABK, Interventional oncology, Medical device

HALIFAX, NS, Dec. 6, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, today announced an oversubscribed USD 30 million Series C financing.

Key Points: 
  • HALIFAX, NS, Dec. 6, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, today announced an oversubscribed USD 30 million Series C financing.
  • The round is co-led by new investors Sant Ventures and a significant, undisclosed MedTech strategic investor.
  • ABKBiomedicalwilldirect thefundingtoseek FDA IDE approval to execute their Eye90 microspheres Route90 US pivotal trial and continue their clinical development programs.
  • "We have made tremendous progress at ABK over the past three years," said Mike Mangano, President and CEO of ABK Biomedical.

Award-winning ABK Bavarian Beer reaches 3,250 venue milestone in the UK

Retrieved on: 
Friday, December 2, 2022
History, ABK, German Gymnasium, London, Australian International Beer Awards, Beer, Gymnasium (Germany), Kings Cross, Hell

LONDON, Dec. 2, 2022 /PRNewswire/ -- ROKiT Drinks, part of the ROKiT Group of Companies co-founded by Jonathan Kendrick and John Paul DeJoria, are delighted to announce that its ABK Beer is now avalable in 3,250 venues across the UK. 

Key Points: 
  • Milestone reached with ABK Beer now available in the iconic German Gymnasium bar in King's Cross, London
    LONDON, Dec. 2, 2022 /PRNewswire/ -- ROKiT Drinks, part of the ROKiT Group of Companies co-founded by Jonathan Kendrick and John Paul DeJoria, are delighted to announce that its ABK Beer is now avalable in 3,250 venues across the UK.
  • Founded in 1308 in Kaufbeuren, Bavaria, ABK Beer proudly continues to use the same locally grown Hallertau hops and grains from the same local farms, represents more than 700 years of Bavarian brewing heritage and tradition.
  • Jonathan Kendrick commented "To achieve the milestone of 3,250 venues offering ABK Beer in the UK with the German Gymnasium is tremendously appropriate!
  • For more information on the German Gymnasium and its specially created menu pairings with ABK Beer, please visit https://www.germangymnasium.com/event/bestselling-bites-abk-pints/

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Retrieved on: 
Monday, September 12, 2022
Glass, Pectus carinatum, Vein, ABK, MD, FDA, Unified school district, Neoplasm, NOT, Program, Patient, HCC, Physician, Technology, Pain, Blood, Arteriovenous malformation, Microparticle, Research, Capillary, Multimedia, Artery, Medical device, Medical imaging, NS

HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors.

Key Points: 
  • HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc. , an innovative medical device company dedicated to the research, development, and commercialization of advanced imageableembolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors.
  • Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition.
  • Hypervascular tumors occur in both benign and malignant states and are characterized by blood supply from an abnormally large number of blood vessels.
  • Microspheres embolization reduces or eliminates the blood flow to these tumors and is an effective interventional radiology therapy for treating this disease state.